Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

New England Journal of Medicine

Volumn 356, Issue 19, 2007, Pages 1928-1943

  Garland, Suzanne M ^a,b   Hernandez Avila, Mauricio ^c   Wheeler, Cosette M ^d   Perez, Gonzalo ^e   Harper, Diane M ^f,g   Leodolter, Sepp ^h   Tang, Grace W K ⁱ   Ferris, Daron G ^j   Steben, Marc ^k   Bryan, Janine ^l   Taddeo, Frank J ^l   Railkar, Radha ^l   Esser, Mark T ^l   Sings, Heather L ^l   Nelson, Micki ^l   Boslego, John ^l   Sattler, Carlos ^l   Barr, Eliav ^l   Koutsky, Laura A ^m  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e National Research Center   (Colombia)

^f NORRIS COTTON CANCER CENTER   (United States)

^g DARTMOUTH MEDICAL SCHOOL   (United States)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ UNIVERSITY OF HONG KONG   (Hong Kong)

^j MEDICAL COLLEGE OF GEORGIA   (United States)

^k INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^l MERCK RESEARCH LABORATORIES   (United States)

^m UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; BRONCHOSPASM; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FEVER; GENITAL TRACT CANCER; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRUS STRAIN; VULVA DISEASE; WART VIRUS;

EID: 34248365967     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa061760     Document Type: Article

References (31)

1. Endo M, Yamashita T, Jin HY, Akutsu Y, Jimbow K. Detection of human papillomavirus type 16 in bowenoid papulosis and nonbowenoid tissues. Int J Dermatol 2003;42:474-6.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
3. Goodman A. Primary vaginal cancer. Surg Oncol Clin N Am 1998;7:347-61.
4. Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 1997;90:448-52.
5. Gissmann L, zur Hausen H. Partial characterization of viral DNA from human genital warts (condylomata acuminata). Int J Cancer 1980;25:605-9.
6. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005;106:1319-26.
7. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
8. Feoli-Fonseca JC, Oligny LL, Brochu P, Simard P, Falconi S, Yotov WV. Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR-direct sequencing approach. J Med Virol 2001;63:284-92.
9. Bosch FX, de Sanjosé S. Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
10. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-604.
11. Green GE, Bauman NM, Smith RJ. Pathogenesis and treatment of juvenile onset recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2000;33:187-207.
12. Derkay CS, Darrow DH. Recurrent respiratory papillomatosis of the larynx: current diagnosis and treatment. Otolaryngol Clin North Am 2000;33:1127-42.
13. Somers GR, Tabrizi SN, Borg AJ, Garland SM, Chow CW. Juvenile laryngeal papillomatosis in a paediatric population: a clinicopathologic study. Pediatr Pathol Lab Med 1997;17:53-64.
14. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
15. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
16. Daling JR, Madeleine MM, Schwartz SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002;84:263-70.
17. Joura EA, Losch A, Haider-Angeler MG, Breitenecker G, Leodolter S. Trends in vulvar neoplasia: increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 2000;45:613-5.
18. Clifford GM, Smith JS, Plummer M, Münoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
19. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21-31.
20. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15.
21. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001;357:1490-3.
22. Castle PE, Hillier SL, Rabe LK, et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 2001;10:1021-7.
23. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
24. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
25. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
26. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Commun Stat Theory Methods 1998;27:1305-22.
27. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002;359:1686-9.
28. Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66.
29. Olsson SE, Villa LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle vaccine. Vaccine (in press).
30. Sobol RE. The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther 2006;13:725-31.
31. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45.